Cargando…

Physiologically‐Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan

A combination of the antipsychotic olanzapine and the opioid receptor antagonist samidorphan (OLZ/SAM) is intended to provide the antipsychotic efficacy of olanzapine while mitigating olanzapine‐associated weight gain. As cytochrome P450 (CYP) 1A2 and CYP3A4 are the major enzymes involved in metabol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Lei, von Moltke, Lisa, Rowland Yeo, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020312/ https://www.ncbi.nlm.nih.gov/pubmed/31919994 http://dx.doi.org/10.1002/psp4.12488

Ejemplares similares

Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination
por: Sun, Lei, et al.
Publicado: (2020)

Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet
por: Sun, Lei, et al.
Publicado: (2021)

Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate
por: Sun, Lei, et al.
Publicado: (2019)

Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet
por: Sun, Lei, et al.
Publicado: (2019)

Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine‐Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study
por: Sun, Lei, et al.
Publicado: (2018)

Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia
por: Sun, Lei, et al.
Publicado: (2021)

The Facts and Fiction of Olanzapine-Samidorphan Fixed Dose Combination
por: Das, Nileswar, et al.
Publicado: (2022)

Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age
por: Kumar, Vipul, et al.
Publicado: (2019)

Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers
por: Toledo, Frederico G. S., et al.
Publicado: (2021)

Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment
por: Grywińska, Weronika B., et al.
Publicado: (2023)

A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine
por: Srisurapanont, Manit, et al.
Publicado: (2021)

Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis
por: Peng, Zhenlei, et al.
Publicado: (2023)

Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
por: Cunningham, Jacobi I, et al.
Publicado: (2019)

Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials
por: Rehan, Syeda Tayyaba, et al.
Publicado: (2022)

Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study
por: Correll, Christoph U, et al.
Publicado: (2022)

Addressing drug safety of maternal therapy during breastfeeding using physiologically‐based pharmacokinetic modeling
por: Pan, Xian, et al.
Publicado: (2022)

Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
por: Jones, HM, et al.
Publicado: (2013)

Physiologically‐Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study
por: Rowland Yeo, Karen, et al.
Publicado: (2020)

T35. A PHASE 3, MULTICENTER STUDY TO ASSESS THE 1-YEAR SAFETY AND TOLERABILITY OF A COMBINATION OF OLANZAPINE AND SAMIDORPHAN IN PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM THE ENLIGHTEN-2-EXTENSION
Publicado: (2020)

A best practice framework for applying physiologically‐based pharmacokinetic modeling to pediatric drug development
por: Johnson, Trevor N., et al.
Publicado: (2021)

A Review of Samidorphan: A Novel Opioid Antagonist
por: Chaudhary, Amna Mohyud Din, et al.
Publicado: (2019)

Physiologically Based Pharmacokinetic Modelling to Predict Imatinib Exposures in Cancer Patients with Renal Dysfunction: A Case Study
por: Rowland Yeo, Karen, et al.
Publicado: (2023)

Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations
por: Johnson, Trevor N., et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling in Pregnant Women Suggests Minor Decrease in Maternal Exposure to Olanzapine
por: Zheng, Liang, et al.
Publicado: (2022)

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies
por: Fava, Maurizio, et al.
Publicado: (2018)

Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model
por: Almond, Lisa M., et al.
Publicado: (2016)

Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans
por: Min, Jee Sun, et al.
Publicado: (2016)

Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
por: Zhou, D, et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
por: Hanke, Nina, et al.
Publicado: (2021)

Risk–Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach
por: Ezuruike, Udoamaka, et al.
Publicado: (2018)

Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug–Drug Interactions Involving Modafinil
por: Rowland, Angela, et al.
Publicado: (2016)

In vivo Characterization of the Opioid Receptor–Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations
por: Tan, Laura A, et al.
Publicado: (2022)

An Integrated Approach for Assessing the Impact of Renal Impairment on Pharmacokinetics of Drugs in Development: Pivotal Role of PBPK Modelling
por: Rowland Yeo, Karen, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling Framework for Quantitative Prediction of an Herb–Drug Interaction
por: Brantley, S J, et al.
Publicado: (2014)

Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates
por: Otsuka, Yukio, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions
por: Britz, Hannah, et al.
Publicado: (2020)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
por: Yoon, Deok Yong, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug–Drug Interactions
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2022)

Application of Physiologically‐Based Pharmacokinetic Modeling to Predict Gastric pH‐Dependent Drug–Drug Interactions for Weak Base Drugs
por: Dong, Zhongqi, et al.
Publicado: (2020)

Pharmacokinetics of olanzapine long-acting injection: the clinical perspective
por: Heres, Stephan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_k09a20c5opltcorbclja50lggj